USPTO Cancer Patents Analyzer is a visualization tool to gain insights from cancer patents data based on USTPO’s curated data set consisting 269,353 patent documents. The data set has published applications and granted patents spanning from 1976 to 2016. The patents records are linked to FDA approved drug and NIH Federal Grants information available from U.S. Food and Drug Administration (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book and he National Institutes of Health (NIH) Research Portfolio Online Reporting Tools (RePORTER) respectively.
The tool provides dashboard and charts for analysis. In summary, the dashboard describes cancer patents data to provide users with counts of total patents, patents funded by NIH grants and patents that were successfully developed into treatments. It also shows a break-down of patent count by patent categories (bar-chart) to show which areas of cancer research has high focus by researchers and funding organization. Furthermore, there is a pie-chart to show how many patents were used to develop cancer treatment from 1976 to 2016 and a time-line chart to show increase or decrease in patent counts over period of time. Following are few key insights that a user can gain from the dashboard and charts:
- Total federal funding received from 1976 to 2016 is just 2.71%.
- Drug and Chemistry, DNA/RNA Protein Sequence and Diagnostic/Surgical Devices has been the top 3 areas for cancer research. Drug and Chemistry patents has received maximum federal funding. All Radiation Measurement patents were federally funded.
- Only 0.4% of patents from 1976 to 2016 has been successfully developed into treatments.
- Maximum number of patents (19,505) were granted in year 2014.
- A decline in number of patents granted is observed from 2014 to 2015 (no significant data available for 2016).
Please access the URL to view the tool and download user guide to help with navigation.